Sökning: WFRF:(Myers Evan R.) > Prophylactic effica...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04630naa a2200721 4500 | |
001 | oai:lup.lub.lu.se:c0f2b2b7-2f15-4dbf-9928-2b4bd278c00c | |
003 | SwePub | |
008 | 160401s2007 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:116232722 | |
024 | 7 | a https://lup.lub.lu.se/record/9690272 URI |
024 | 7 | a https://doi.org/10.1086/5228642 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1162327222 URI |
040 | a (SwePub)lud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Villa, Luisa L.4 aut |
245 | 1 0 | a Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection |
264 | 1 | b Oxford University Press (OUP),c 2007 |
520 | a Background. A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6,-11,-16, and-18 in 16-26-year-old women naive for HPV vaccine types. Because most women in the general population are sexually active, some will have already been infected with >= 1 HPV vaccine types at the time vaccination is offered. Here, we assessed whether such infected women are protected against disease caused by the remaining HPV vaccine types. Methods. Two randomized, placebo-controlled trials of the quadrivalent (types 6, 11, 16, and 18) HPV vaccine enrolled 17,622 women without consideration of baseline HPV status. Among women infected with 1-3 HPV vaccine types at enrollment, efficacy against genital disease related to the HPV vaccine type or types for which subjects were naive was assessed. Results. Vaccination was 100% effective (95% confidence interval [CI], 79%-100%) in preventing incident cervical intraepithelial neoplasia 2 or 3 or cervical adenocarcinoma in situ caused by the HPV type or types for which the women were negative at enrollment. Efficacy for preventing vulvar or vaginal HPV-related lesions was 94% (95% CI, 81%-99%). Conclusions. Among women positive for 1-3 HPV vaccine types before vaccination, the quadrivalent HPV vaccine protected against neoplasia caused by the remaining types. These results support vaccination of the general population without prescreening. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng |
700 | 1 | a Perez, Gonzalo4 aut |
700 | 1 | a Kjaer, Susanne Krueger4 aut |
700 | 1 | a Paavonen, Jorma4 aut |
700 | 1 | a Lehtinen, Matti4 aut |
700 | 1 | a Munoz, Nubia4 aut |
700 | 1 | a Sigurdsson, Kristjan4 aut |
700 | 1 | a Hernandez-Avila, Mauricio4 aut |
700 | 1 | a Iversen, Ole Eric4 aut |
700 | 1 | a Thoresen, Steinar4 aut |
700 | 1 | a Garcia, Patricia J.4 aut |
700 | 1 | a Majewski, Slawomir4 aut |
700 | 1 | a Tay, Eng Hseon4 aut |
700 | 1 | a Bosch, F. Xavier4 aut |
700 | 1 | a Dillner, Joakimu Karolinska Institutet,Lund University,Lunds universitet,Klinisk mikrobiologi, Malmö,Forskargrupper vid Lunds universitet,Clinical Microbiology, Malmö,Lund University Research Groups4 aut0 (Swepub:lu)mikr-jdi |
700 | 1 | a Olsson, Sven-Ericu Karolinska Institutet4 aut |
700 | 1 | a Ault, Kevin A.4 aut |
700 | 1 | a Brown, Darron R.4 aut |
700 | 1 | a Ferris, Daron G.4 aut |
700 | 1 | a Koutsky, Laura A.4 aut |
700 | 1 | a Kurman, Robert J.4 aut |
700 | 1 | a Myers, Evan R.4 aut |
700 | 1 | a Barr, Eliav4 aut |
700 | 1 | a Boslego, John4 aut |
700 | 1 | a Bryan, Janine4 aut |
700 | 1 | a Esser, Mark T.4 aut |
700 | 1 | a Hesley, Teresa M.4 aut |
700 | 1 | a Nelson, Micki4 aut |
700 | 1 | a Railkar, Radha4 aut |
700 | 1 | a James, Margaret4 aut |
700 | 1 | a Sattler, Carlos4 aut |
700 | 1 | a Taddeo, Frank J.4 aut |
700 | 1 | a Thornton, Annemarie R.4 aut |
700 | 1 | a Vuocolo, Scott C.4 aut |
710 | 2 | a Klinisk mikrobiologi, Malmöb Forskargrupper vid Lunds universitet4 org |
773 | 0 | t Journal of Infectious Diseasesd : Oxford University Press (OUP)g 196:10, s. 1438-1446q 196:10<1438-1446x 1537-6613x 0022-1899 |
856 | 4 | u http://dx.doi.org/10.1086/522864x freey FULLTEXT |
856 | 4 | u https://academic.oup.com/jid/article-pdf/196/10/1438/18049618/196-10-1438.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/969027 |
856 | 4 8 | u https://doi.org/10.1086/522864 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:116232722 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.